MagnetisMM-7
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 760 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody, GPRC5D
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1322
- NCT Identifier
- NCT05317416
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.